Citations

Clear

4798 citation(s) found for "Ku, Jennifer H".

Delirium and Long-Term Cognitive Trajectories in Cognitively Unimpaired Adults
St Sauver, Jennifer, Schafer, Marissa

Mayo Clinic

JAMA Neurology | November 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.4001 | PMID 42970282 Get It

Importance Delirium is a state of acute confusion characterized by deficits in attention that occurs commonly during hospitalization and is associated with adverse outcomes; however, the association of delirium with longitudinal cognitive trajectories is not fully understood. Objective To evaluate the association of delirium during hospitalization with subsequent development of mild cognitive impairment (MCI), dementia, and longitudinal cognitive trajectories. Design, Setting, and Participants This cohort study used data from participants with hospitalizations in the Mayo Clinic Study of Aging (MCSA) from October 2004 to December 2023. The MCSA is a prospective, population-based longitudinal study of cognitive aging among residents of Olmsted County, Minnesota. Of participants enrolled in the MCSA between 2004 and 2023, individuals who experienced 1 or more hospitalization prior to their last MCSA encounter were included in this study. Participants with dementia at MCSA enrollment or prior to first hospitalization were excluded. Follow-up continued until development of MCI or dementia, last MCSA visit, or the end of the study. Exposure Delirium was identified using a validated natural language processing algorithm applied to clinical notes from hospitalizations, associated emergency department visits, and follow-up within 30 days after hospitalization. Delirium status was modeled as a time-dependent exposure. Main Outcomes and Measures Incident MCI and dementia were assigned through MCSA expert consensus evaluations, including neuropsychological testing performed every 15 months. Association between delirium and development of MCI or dementia was assessed using Cox proportional hazards regression, adjusted for patient age, sex, level of education, and apolipoprotein E (APOE) ε4 allele carrier status; cognitive trajectories were assessed with linear mixed-effects models. Results Of 7030 participants enrolled in the MCSA, 3542 individuals experienced 1 or more hospitalization prior to their last MCSA encounter and were included, and 41 participants with dementia at enrollment or prior to first hospitalization were excluded. The cohort included 3501 participants with at least 1 hospitalization. Median (IQR) age was 74.1 (66.6-80.9) years, 1676 participants (47.9%) were female, median (IQR) level of education was 14 (12-16) years, and 910 participants (26.0%) were APOE ε4 carriers. During a median (IQR) follow-up of 7.2 (4.1-10.4) years, 75 participants (2.1%) had delirium documented within 30 days of hospitalization. Delirium was associated with increased risk of MCI (adjusted hazard ratio [aHR], 3.67; 95% CI, 2.19-6.15) and dementia (aHR, 5.39; 95% CI, 2.94-9.85) and with accelerated decline in longitudinal cognitive testing. Conclusions and Relevance In this cohort study among adults in the MCSA, including those with unimpaired cognition at baseline, delirium during hospitalization was strongly associated with increased risk of MCI and dementia and accelerated cognitive decline in subsequent years.
The characteristics of perivascular proinflammation in 4‐repeat tauopathies
Fu, Mu-Hui , Uruk, Gokhan , Whitwell, Jennifer L , Whitwell, Jennifer , Josephs, Keith A

Mayo Clinic

Brain Pathology | October 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bpa.70162 | PMID 42950799 Get It

Abstract Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are both neurodegenerative diseases characterized by aggregates composed of 4‐repeat (4R) tau protein. They have distinct neuropathological features and classic clinical symptoms; however, the signs and symptoms overlap across the two syndromes. Accumulating evidence suggests that dysregulated immune response is a major contributing factor to neurodegeneration but its role in 4R‐tauopathies remains undetermined. The aim is to explore the involvement of neuroinflammation from a vascular perspective in 4R‐tauopathies. Autopsies from four controls, three PSP, and three CBD cases were assessed. Samples were obtained from the superior/middle frontal gyrus (S/M‐FG) and basal ganglia (BG). Immunofluorescence staining included neuroinflammatory markers: glial fibrillary acidic protein (GFAP), ionized calcium‐binding adapter molecule 1 (Iba1), cluster of differentiation 68 (CD68); vascular markers: collagen type IV (ColIV), monocarboxylate transporter‐1 (MCT1), and α‐smooth muscle actin ( α SMA). Maximally projected confocal z‐stack images of vasculature were used as a mask to quantify total perivascular GFAP+/Iba1+/CD68+ labeling. GFAP immunoreactivity ratio between MCT1 and α SMA double labeled arteries and veins was quantified to further differentiate venular and arteriolar involvement into proinflammatory activation. Both PSP and CBD had widespread perivascular proinflammatory changes, although greater in CBD. The activated GFAP+ astrocytes and microglia/macrophages in CBD were distributed extensively in S/M‐FG and BG, with S/M‐FG WM more affected. In PSP, abundant neuroinflammation was found in BG. The involvement of vasculature type was distinct among the two 4R‐tauopathies, while CBD showed comparable proinflammatory changes in arterioles and venules, PSP exhibited predominant proinflammation in venules. The regional pattern of perivascular proinflammation differed between PSP and CBD, corresponding to the characteristic affected brain regions. CBD had more severe perivascular proinflammation that involved both arterioles and venules, while venules were more affected in PSP. Perivascular proinflammation may be a critical pathophysiological process in 4R‐tauopathies.
A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01
Borad, Mitesh J. , Busset, Michele Droz Dit , Javle, Milind , Shaib, Walid L. , Personeni, Nicola , Mody, Kabir , Bergamo, Francesca, Harris, William P., Damjanov, Nevena , Macarulla, Teresa , Brandi, Giovanni , Masi, Gianluca , Abou‐Alfa, Ghassan K. , Hálfdánarson, Þorvarður R. , Knox, Jennifer, Tam, Vincent C. , Bernat, Mathieu, Engelhardt, Marc , Friedmann, Silke, Häckl, Manuel, McKernan, Phil, Saulay, Mikael, Goff, Laura W. , Hollebecque, Antoine , Adeva, Jorge , Jeffry Evans, Thomas R. , Bridgewater, John , Foerster, Friedrich , Kendall, Stephan DiSean, Roth, Gaël , Cunningham, David, Vogel, Arndt , Niger, Monica , Mahipal, Amit , Mazzaferro, Vincenzo

Mayo Clinic

Hepatology | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001902 | PMID 42937546 Get It

Background & Aims: To evaluate safety and efficacy of FGFR1–3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements ( FGFR2 F ), mutations ( FGFR2 M ), or amplifications ( FGFR2 A ), previously treated with chemotherapy. Approach & Results: Open-label, non-controlled Phase 2 trial. Patients with advanced iCCA, ≥1 prior chemotherapy, and FGFR2 F (Substudy 1) or FGFR2 M /FGFR A (Substudy 2), received once-daily oral derazantinib 300 mg until disease progression, unacceptable toxicity, consent withdrawal or investigator decision to stop. Efficacy was assessed by central radiology review using RECIST v1.1. Primary endpoints were objective response rate (ORR; Substudy 1) and 3-month progression-free survival (PFS3; Substudy 2). Other endpoints were PFS, ORR (Substudy 2), disease control rate (DCR), duration of response (DOR), and overall survival (OS). In Substudy 1, ORR and DCR were 22.3% (23/103 partial responses) and 75.7%, respectively; median (95% CI) PFS was 8.1 (5.5,8.3) months, DOR was 6.5 (4.6,9.2) months, and OS was 17.2 (12.5,22.4) months. In Substudy 2, PFS3 was 63% (27/43), ORR was 9.3% (3 partial, 1 complete response), DCR was 69.8%, and OS was 11.9 (8.4,15.9) months. There were no Grade 4 or 5 drug-related events. FGFR inhibitor class-specific toxicities included drug-related hyperphosphataemia (38%, Grade 3: 3%) and dry eye (36%). Nail disorders (10%, any grade or causality), stomatitis (5%), retinal events (5%), and palmar-plantar erythrodysesthesia (1%) were infrequent. Conclusions: In previously chemotherapy treated, FGFR-inhibitor-naïve patients with iCCA harboring FGFR2 fusions, mutations, or amplifications, derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile.
The Congenital Heart Surgeons’ Society Center for Research and Quality 2025 Annual Report
Jacobs, Jeffery P , DeCampli, William M , Honjo, Osami , Alsoufi, Bahaaldin , Jegatheeswaran, Anusha , Louis, James D. St. , Lambert, Linda M , Manlhiot, Cedric , Kumar, S Ram , Kirklin, James K. , Austin, Erle H , Overman, David M , Dearani, Joseph A. , Romano, Jennifer C , Blackstone, Eugene H.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21501351261477040 | PMID 42876309 Get It

The Congenital Heart Surgeons’ Society (CHSS) is viewed by many as one of the most prestigious professional societies dedicated to pediatric and congenital cardiac surgery. The CHSS Center for Research and Quality (CRQ) Fall 2025 Work Weekend was held in Chicago on Saturday, October 25, 2025. The purpose of this article is to summarize the proceedings of the CHSS CRQ Fall 2025 Work Weekend and to provide a 2025 Annual Report of the CHSS CRQ. At the CHSS CRQ Fall 2025 Work Weekend, multiple topics were discussed related to ongoing CHSS research and quality initiatives. The CHSS CRQ is evolving to keep pace with the rapid evolution of medical informatics and the ever-evolving regulatory issues of clinical research. This 2025 Annual Report of the CHSS CRQ summarizes some of the ongoing initiatives at CHSS CRQ designed to assure that the CHSS CRQ continues to lead innovative and collaborative clinical research to improve pediatric and congenital cardiac care.
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe, Matthew M , Le-Rademacher, Jennifer G , Haffty, Bruce G , Hansen, Eric K , Wagner, Jamie L , Kong, Iwa , Whelan, Timothy J , Kour, Odum, Lee, Minji K , Ruddy, Kathryn J , Partridge, Ann H , Carey, Lisa A , Lustberg, Maryam , Chow, Selina , Stecklein, Shane Richard , Gaffney, David K , Khan, Atif J.

Mayo Clinic

Journal of Clinical Oncology | October 12, 2026 | Volume: 44 | Issue: 32 | Pages: 3128-3138

10.1200/jco-26-00474 | PMID 42863096 Get It

PURPOSE Patients with breast cancer requiring postmastectomy radiation therapy (PMRT) often desire breast reconstruction. Reconstructions can be adversely affected by PMRT, and fear of reconstruction complications has discouraged adoption of short-course radiation therapy used after lumpectomy. To fill the evidence gap, we conducted a noninferiority trial of hypofractionated versus conventional PMRT in patients undergoing breast reconstruction. The primary outcome was reconstruction complication rate, a composite of wound healing, readmission, capsular contracture, unplanned reoperation, and reconstruction failure. METHODS Women with unilateral invasive breast cancer with planned immediate or delayed reconstruction and PMRT were randomly assigned (1:1) to 50 Gy (25 fractions/5 weeks) or 42.56 Gy (16 fractions/3 weeks). This study was designed with a noninferiority margin of 10%, assuming a 2-year reconstruction complication rate of 25% with conventional PMRT. Randomization was stratified by immediate versus delayed and autologous versus implant-only reconstruction. RESULTS Between 2018 and 2021, 898 patients enrolled with a median follow-up of 3.9 years; 825 patients were evaluable for the primary end point. The 24-month reconstruction complication rates were 12.3% (52/422) with hypofractionated PMRT and 10.2% (41/403) with conventional PMRT, corresponding to an estimated difference of -2.1% (95% CI, -6.5 to 2.2). The complication rate was higher (regardless of arm) with implant-only versus autologous reconstruction (odds ratio = 1.65). There was no statistically significant difference in 36-month locoregional recurrence rates: 1.5% (95% CI, 0.7 to 3.2) with hypofractionated and 2.2% (95% CI, 1.1 to 4.3) with conventional PMRT. Acute and late toxicity rates were not statistically different. CONCLUSION A 16-fraction course of hypofractionated PMRT is safe and noninferior to conventional PMRT in women undergoing breast reconstruction after mastectomy.
TDP-43 Coincides with Noradrenergic Neurons in Alzheimer’s Disease (AD) and Primary Age-Related Tauopathy (PART)
Youseff, Hossam , Whitwell, Jennifer L , Hossain, Nadia , Bhaskaran, Jerusha , Machulda, Mary M , Whitwell, Jennifer , Reichard, Robert Ross, Josephs, Keith A

Mayo Clinic

Cells | October 12, 2026 | Volume: 15 | Issue: 20 | Pages: 1850

10.3390/cells15201850 | PMID 42929824 Get It

TAR DNA-binding protein 43 (TDP-43) pathology is a major contributor to cognitive decline in Alzheimer’s disease (AD), yet the cellular substrates and circuit-level consequences of its limbic accumulation remain poorly defined. Here, we combined multiplex immunofluorescence with 3D Artificial Intelligence (AI)-based object detection and quantitative colocalization to map phosphorylated TDP-43 (pTDP-43) across neuronal subtypes in the amygdala, hippocampal subfields, and entorhinal cortex (ERC) in human AD, AD with Lewy body disease (AD-LBD), and primary age-related tauopathy (PART). Across 15 deeply phenotyped cases, pTDP-43 showed preferential accumulation in neuromodulatory noradrenergic neurons, with more limited involvement of glutamatergic terminals and cholinergic populations. Noradrenergic neurons marked by dopamine β-hydroxylase (DβH) demonstrated extensive colocalization with pTDP-43 across regions, correlating with APOE genotype, amyloid burden, and tau staging in this cross-sectional cohort, suggesting that neuromodulatory circuits might represent a major convergence point for AD-related molecular stressors. Dopaminergic (tyrosine hydroxylase (TH)) and cholinergic (choline acetyltransferase (ChAT)) neurons showed more restricted but pathology-dependent involvement, with LBD consistently showing lower pTDP-43 burden across multiple transmitter systems. Glutamatergic vesicular glutamate transporter-1 (VGLUT1)-positive neurons and terminals exhibited minimal colocalization except in PART. Principal component (PCA) and hierarchical clustering analyses (HCA) integrating pTDP-43 colocalization with neuropathologic staging metrics (A, B, C, Thal, Braak, LBD) reliably separated PART, AD-TDP, and AD-TDP-LBD groups, with LBD emerging as a dominant modifier of cellular vulnerability. Together, these findings point out that TDP-43 pathology in AD preferentially targets neuromodulatory circuits, is strongly shaped by coexisting synucleinopathy, and provides a cell-type-resolved framework for understanding how TDP-43 contributes to limbic network dysfunction in neurodegeneration.
Retrieval-to-abstraction LLM-assisted literature synthesis: Case demonstrations in digital health technology-enabled randomized controlled trial outcome reporting
Harrison, Taylor B , Hu, Dian , Chen, Fang , Hoy, Matt, St Sauver, Jennifer

Mayo Clinic

PLOS Digital Health | October 9, 2026 | Volume: 5 | Issue: 10 | Pages: e0001768

10.1371/journal.pdig.0001768 | PMID 42853800 Get It

Systematic reviews of randomized controlled trials (RCTs) support evidence-based clinical advancement. Clinical trial reporting guidelines, including CONSORT, establish common data elements that support systematic synthesis of published trial outcomes. However, the rapid rise of digital health technologies presents new challenges for reporting guidelines, and substantial real-world reporting heterogeneity has been observed. Therefore, machine-assisted evaluation of reporting adherence offers a pathway for more agile information management to accommodate the diverse and disruptive nature of digital health technology-enabled RCTs. Here, we propose an accelerated retrieval-to-abstraction literature synthesis framework to conduct article screening, text and table data preprocessing, and full-text review using an unmodified pretrained large language model. We apply this methodology in two digital health technology-enabled RCT case studies evaluating adherence to technology and digital health equity guideline reporting items. Large language model performance was on par with inter-annotator agreement F1 scores (≥0.9) in both screening and information-extraction tasks. These findings support the scalability and rigor of accelerated evidence synthesis and demonstrate the importance of common reporting elements across digital health technology-enabled RCTs.
Clinical and genetic characterization of FUS -associated ALS in a tertiary cohort
Bettoni, Veronica, Nath, Samir R. , Bojko, Alissa, Salmaninejad, Arash , Tan-Arroyo, Jennifer

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | October 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1080/21678421.2026.2743446 | PMID 42839902 Get It

Longitudinal Surgical Modeling of Early Glioblastoma Recurrence Reveals Emergence of Margin-Associated Neural Programs
Malla, Adarsha P. , Flick, Matthew , Fang, Jennifer R. , Fan, Xiaoxuan , Chen, Chixiang , Beniwal, Angad , Sereduk, Chris , Drexler, Richard , Poulopoulos, Alexandros , Monje, Michelle , Anastasiadis, Pavlos , Tran, Nhan L. , Winkles, Jeffrey A.

Mayo Clinic

Cancer Research | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF20

10.1158/0008-5472.can-25-5176 | PMID 42831833 Get It

Abstract Glioblastoma (GBM) is a lethal, treatment-resistant brain cancer characterized by diffuse brain invasion, complex neuron–glioma signaling, and cellular, molecular, and spatial heterogeneity. Surgery is the current mainstay of treatment, aimed at maximizing tumor cytoreduction, decompressing the brain to improve neurologic function and providing material for analyses to inform prognostication and adjuvant treatment selection. To accurately model GBM surgical resection and tissue sampling in preclinical animal models, we developed the Maximal Safe Intracranial Surgery (MSIS) platform. MSIS integrated a miniaturized neurosurgical resection device and enabled a safe, tunable, and reproducible approach for intracranial tumor resection, multiregional biopsy, and longitudinal tissue sampling in murine models, with stereotactic, sterile, and high-viability tissue collection. MSIS was applied across five distinct orthotopic brain tumor models to reproducibly generate histologically and radiologically representative models of postsurgical GBM. Similar to humans, increasing the extent of resection correlated with improved animal survival, and recurrent growth patterns varied significantly by model type. Transcriptional profiles of matched primary versus postsurgical recurrent tumors revealed enrichment of margin-associated transcriptional states consistent with neuron–glioma signaling. Overall, the MSIS approach offers opportunities to model the standard of care, dissect the spatial and temporal dynamics of GBM, and pair therapeutic discovery with contextual tumor pathobiology. Significance: A clinically derived stereotactic resection platform models surgical resection in glioblastoma, enabling longitudinal tissue sampling and revealing conserved early-recurrence neuron-glioma programs in patient-derived models.